Avalo Therapeutics Highlights AVTX-009 Plan, Near-Term Phase II HS Data at Healthcare Conference

Avalo Therapeutics (NASDAQ:AVTX) used a presentation at its 46th Annual Healthcare Conference appearance to outline its strategy for AVTX-009, a high-affinity human monoclonal antibody designed to ...
Benzinga.com

Black Diamond's Lung Cancer Drug Shows 60% Response Rate In Phase 2 Data

The company expects to present updated results from the Phase 2 NSCLC trial, including Duration of Response (DOR) and Progression-free Survival (PFS) data in both the recurrent (83 patients) and ...
Nasdaq

Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer

These results are particularly meaningful, as the landscape of MSS colorectal cancer treatment has seen little advancement leaving a significant gap in effective therapies for patients. “MSS ...
Nasdaq

Vigil Neuroscience Advances VG-3927 into Phase 2 Trial as a Promising Once-Daily Oral Therapy for Alzheimer's Disease Following Positive Phase 1 Results

Vigil Neuroscience, Inc. announced positive Phase 1 clinical trial results for VG-3927, a potential once-daily oral therapy for Alzheimer’s disease (AD). The trial demonstrated favorable safety, ...